Tissue Sodium Quantification in Patients With Primary Aldosteronism: See Sodium to Treat

Launched by JENS TITZE · Aug 21, 2024

Keywords

ClinConnect Summary

This clinical trial, titled "Tissue Sodium Quantification in Patients With Primary Aldosteronism: See Sodium to Treat," is studying a condition called primary aldosteronism (PA), which can cause high blood pressure. Researchers believe that people with PA may store too much sodium (a type of salt) in their muscles. By using a special type of MRI scan called 23NaMRI, they aim to measure the amount of sodium in the muscles without needing invasive procedures. This information could help improve the diagnosis and treatment of PA in the future, similar to how a blood test called HbA1c helps manage diabetes.

To participate in this study, individuals need to be between 21 and 70 years old and have high blood pressure or be suspected of having primary aldosteronism, based on medical guidelines. Participants must be able to provide informed consent and should not have certain medical conditions that could interfere with the MRI scan, such as having metal implants or severe health issues. Those who join the study can expect to undergo non-invasive imaging to help researchers learn more about sodium levels in their muscles, potentially leading to better treatments for their condition.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age 21-70 years, with arterial hypertension or suspected to have primary aldosteronism based on Endocrine Society Guidelines.
• • 2. Male and female patients older than 21 years.
• • 3. Willingness to participate and ability to provide informed consent.
• Exclusion Criteria:
• 1. Patients with exclusion criteria for the MRI, such as:
• • implanted devices (surgical clips, heart pacemakers or defibrillators, cochlear implants)
• • iron-based tattoos
• • any other pieces of metal or devices that are not MR-Safe anywhere in the body
• • patients who exhibit noticeable anxiety and/or claustrophobia into the MRI scanner
• • pregnancy
• • 2. Diagnosis of heart failure NYHA classes III and IV
• • 3. Impaired renal function with eGFR\<30 ml/min or proteinuria \> 1 g/24h
• • 4. Liver disease with cirrhosis (Child-Pugh class C) or hypoalbuminemia
• • 5. Muscular dystrophies
• • 6. Patients with active cancer or severe comorbid conditions likely to compromise survival or study participation
• • 7. Unwillingness or other inability to cooperate